Latest Breaking News On - பியர் லூயிஸ் ஜெர்மைன் - Page 7 : comparemela.com

NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. (“PharmaEngine”) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012. As previously disclosed in the Nanobiotix prospectus filed with the U.S. Securities and Exchange Commission on December 11, 2020, in November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the License and Collaboration agreement. In a letter dated December 1, 2020, PharmaEngine responded to the Company’s notification of material breach, denying a material breach of the Licens

United kingdomFrance generalBrandon owensKate mcneilPierre louis germainExchange commission onFrench financial markets authority autoritCommunications departmentInvestor relations departmentPharmaengine incRegulatory newsExchange commissionNasdaq global select marketPrivate securities litigation reform actFrench financial markets authorityDes march